-transparent.png){kind=logo}
The development of ascites in pulmonary arterial hypertension (PAH) in the absence of pre-existing hepatic dysfunction is usually associated with decompensated right heart failure or cardiac cirrhosis. Ascites in PAH has rarely been associated with intravenous epoprostenol, a synthetic form of the prostaglandin PGI2.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Noah C Schoenberg, and
Nicole F Ruopp, and
Raj D Parikh, and
Harrison W Farber
December 2013,
Annals of the American Thoracic Society,
Noah C Schoenberg, and
Nicole F Ruopp, and
Raj D Parikh, and
Harrison W Farber
January 2009,
Expert opinion on drug metabolism & toxicology,
Noah C Schoenberg, and
Nicole F Ruopp, and
Raj D Parikh, and
Harrison W Farber
January 2015,
Acta medica Okayama,
Noah C Schoenberg, and
Nicole F Ruopp, and
Raj D Parikh, and
Harrison W Farber
January 2009,
Chest,
Noah C Schoenberg, and
Nicole F Ruopp, and
Raj D Parikh, and
Harrison W Farber
January 2015,
Vascular health and risk management,
Noah C Schoenberg, and
Nicole F Ruopp, and
Raj D Parikh, and
Harrison W Farber
August 2021,
Expert review of clinical pharmacology,
Noah C Schoenberg, and
Nicole F Ruopp, and
Raj D Parikh, and
Harrison W Farber
September 2010,
Journal of perinatology : official journal of the California Perinatal Association,
Noah C Schoenberg, and
Nicole F Ruopp, and
Raj D Parikh, and
Harrison W Farber
November 2000,
American journal of respiratory and critical care medicine,
Noah C Schoenberg, and
Nicole F Ruopp, and
Raj D Parikh, and
Harrison W Farber
September 2021,
Cureus,
Noah C Schoenberg, and
Nicole F Ruopp, and
Raj D Parikh, and
Harrison W Farber
April 2005,
The Annals of pharmacotherapy,
